None listed
Conditions
Interventions
PATIENTS RECEIVE THIS TEST OR TAMOXIFEN LETROZOLE DISCRETION OF YOUR PHYSICIAN. LETROZOLE PATIENTS BE TREATED WITH INVOLVED IN A PHASE III TRIAL OF MORE BEVACIZUMAB letrazole PRIMERIO IS AIMING SLP. P
24 months versus> 24 MONTHS). PROTOCOL WILL BE CLOSED TO PATIENTS AND TAMOXIFEN letrazole WHEN HAS THE 352 PATIENTS WITH CUMULATIVE LETROZOLE, OR IF THE TEST IS STOPPED EARLY letrazole Futility, REGAR
Sponsors
GRUPO DE ESTUDIOS CLINICOS ONCOLOGICO DEL PERU GECOPERU, CANCER AND LEUKEMIA GROUP B (CALGB),
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: ALL QUESTIONS TO CONSIDER THE SELECTION CRITERIA SHOULD BE DIRECTED TO STUDY CALGB ADDRESS: PLEASE NOTE THAT THE STUDY ADDRESS CAN NOT GRANT THE WAIVER ELIGIBILITY REQUIREMENTS. 4.1 DOCUMENTATION HISTOLOGIC: HISTOLOGIC CONFIRMATION INVASIVE BREAST CANCER FEMALE IN THE STADIUM PRIMARY OR METASTATIC. 4.1.1 STADIUM: DISEASE IN STAGE IV OR IIIB (USING THE CRITERIA AJCC 6TH EDITION) NO LOCAL THERAPY SENSITIVE. 4.2 PATIENT MAY NOT HAVE A MALIGNANT TUMOR CURRENT ASSETS THAN NON MELANOMA SKIN CANCER. PATIENTS ARE NOT CONSIDERED TO HAVE A MALIGNANT TUMOR CURRENT ASSETS IF THEY HAVE COMPLETED TERAPLA AND ARE CONSIDERED BY YOUR DOCTOR WITH LESS THAN 30% OF RISK OF RECURRENCE. 4.3 HORMONE RECEPTOR STATUS: TUMORS (SITES BOTH PRIMARY AND METASTATIC) MUST STATE THE ESTROGEN RECEPTOR (ER) AND / OR PROGESTERONE (PgR) ≥ 1% POSITIVE CELL BE CONSIDERED. 4.4 AGE ≥ 18 YEARS. 4.5 STATUS MENOPAUSAL 4.5.1 POSTMENOPAUSAL WOMEN ARE ELIGIBLE FOR THIS TEST. PRIOR TO REGISTRATION STATUS TO STUDY TO BE DEFINED MENOPAUSAL TO THE CRITERIA DESCRIBED BELOW. POSTMENOPAUSAL 4.5.2 ARE DEFINED AS: • ≥ 55 YEARS OLD AND A YEAR OR MORE OF AMENORRHEA • AGE <55 YEARS AND ONE YEAR OR MORE OF AMENORRHEA, ESTRADIOL WITH A TEST <20 pg / ml.
Exclusion criteria
Exclusion criteria: NO APLICABLE - ONLY IS CONSIDERED SELECTION CRITERIA
Countries
Puerto Rico, United States
Outcome results
None listed